Shares of Shield Therapeutics plc (LON:STX – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 2.72 ($0.03) and traded as low as GBX 2.27 ($0.03). Shield Therapeutics shares last traded at GBX 2.40 ($0.03), with a volume of 9,722,382 shares changing hands.
Shield Therapeutics Stock Performance
The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a market cap of £18.27 million, a PE ratio of -58.40 and a beta of 1.42. The business’s 50-day moving average is GBX 2.71 and its 200 day moving average is GBX 3.22.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- How to trade using analyst ratings
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Why Are These Companies Considered Blue Chips?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
